Rznomics Cooperates with Chungbuk National University Veterinary college to Develop Treatment for Intractable Diseases.

Collaboration throughout preclinical research using RNA-based technology

Rznomics announced on the 1st that it has signed a business agreement with Chungbuk National University Veterinary College to develop a treatment for incurable diseases using ribonucleic acid (RNA)-based technology.

The two organizations decided to cooperate in preclinical research to develop gene therapy. Academic human and material resources will be exchanged for research on animal models for intractable diseases and preclinical treatment for effectiveness and safety verification.

Sang-hwan Hyun, dean of Chungbuk National University's College of Veterinary Medicine, said, "We hope that the joint R&D of RNA-based gene therapy with a new mechanism will contribute to providing new treatment opportunities to patients with intractable diseases with high medical demand."

"We will combine Rznomics's next-generation RNA-based platform technology with experience in basic and preclinical research at Chungbuk National University's veterinary college," said Sung-woo Hong, vice president of Rznomics.